Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

NCT07750951 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

Interventions

DRUG: Cindilimab、IBI310、Capecitabine、Oxaliplatin

Sponsor

Xijing Hospital